January 04, 2021 Unhappy new year for Calithera The company welcomes in 2021 with the failure of a pivotal study of its pipeline lead, telaglenastat.
December 18, 2020 First-quarter catalysts for the smaller players Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
September 30, 2020 Clinical data focus for the smallest players Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
September 05, 2019 Esmo 2019 preview – Parps on parade Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.